London, England. For immediate release-May 11th, 2009
IXICO, Ltd., a global imaging technology and service company, announced today that it has opened its US operations in Chicago, Illinois. The new entity, formally known as IXICO US LLC, is owned in entirety by IXICO, Ltd., of London, England.
IXICO’s US office will provide business development and project management support to its expanding US customer base. The US office will also help facilitate IXICO’s planned expansion of its imaging center network and partnership alliance.
“We are very excited to extend our functional capabilities across the Atlantic, and Chicago provides a perfect central location to support our customers on both coasts,” said Derek Hill, Ph.D., IXICO’s founding CEO. “Chicago also provides a rich environment of imaging expertise at its local universities, as well as a pool of highly educated, well trained professionals in clinical trials project management.”
IXICO US will be managed by Ciaran Mark Cooper, Vice President US Business Development. “Our extended operational footprint is the perfect complement to our expanding business core,” said Cooper. “In addition to our full-service ICRO capabilities, we have recently released several new web-based image management tools that offer terrific value to our customers, both large and small. These tools can help optimize the communication and image management in the execution of imaging trials while providing significant time and cost savings to our clients. Our US expansion is a further indication of our growing business and continuing success.”
About IXICO
IXICO offers a full range of Imaging CRO services including comprehensive, technology-based solutions for the pharmaceutical, biotech and medical device industries across all therapeutic areas and clinical trial phases. IXICO recently released Trial Wire, its free, web-based image management tool. IXICO works within an ISO9001:2000 certified Quality Management System.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.